Area of research
Hematology · Genetics
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors
Ocular graft-versus-host disease: Experience, incidence, and treatment outcomes at a university-based tertiary care ophthalmology center
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Caring for Transplant Recipients in a Setting of Restricted Resources
First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises
Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Durable Clinical Benefits in Severe Sickle Cell Disease with Exagamglogene Autotemcel
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
“Window of Opportunity” in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports
The role of registries in hematological disorders
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation
Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
High dose total marrow irradiation (<scp>TMI</scp>) does not increase long‐term toxicity of myeloablative fludarabine/busulfan (<scp>FluBu4</scp>) conditioning regimen in allogeneic hematopoietic stem cell transplantation (<scp>HSCT</scp>)
Elimination of Vaso-Occlusive Crises after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease
High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT).
Exagamglogene Autotemcel for Severe Sickle Cell Disease
American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting
American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting.
Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes
Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease
Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes
Knowledge-based planning for multi-isocenter VMAT total marrow irradiation
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease
Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease
Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program